CTRL Therapeutics

CTRL Therapeutics is a biotechnology company developing the next generation of cell therapy platforms, which has the potential to open a new frontier in cell therapy for solid tumors. The company’s proprietary method for identifying and isolating circulating tumor-reactive lymphocytes (cTRL) has broad applicability across many solid tumors, with the potential to address long-standing challenges associated with cell therapy and offers key advantages over tumor-infiltrating lymphocytes.